Targeting Axl/EZH/Sox2 for glioblastoma multiform by novel biodegradable interstitial delivery system The IND of Cerebracaandreg;wafer has been approved by FDA for phase I/IIa. This clinical trial has been conducted at Tzu-Chi University Hospital in, Hualien, Taiwan
order to overcome the limitation of blood-brain barrier, a local interstitial delivery system which BP incorporated into a biodegradable polyanhydride material CPPSA, namely, the BP/polymer wafer was applied…

